ATE325117T1 - 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten - Google Patents

3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten

Info

Publication number
ATE325117T1
ATE325117T1 AT03715209T AT03715209T ATE325117T1 AT E325117 T1 ATE325117 T1 AT E325117T1 AT 03715209 T AT03715209 T AT 03715209T AT 03715209 T AT03715209 T AT 03715209T AT E325117 T1 ATE325117 T1 AT E325117T1
Authority
AT
Austria
Prior art keywords
dihydrocinolin
compounds
receptor antagonists
nr2b receptor
nr2b
Prior art date
Application number
AT03715209T
Other languages
German (de)
English (en)
Inventor
M Kawamura
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE325117T1 publication Critical patent/ATE325117T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03715209T 2002-04-26 2003-04-15 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten ATE325117T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37593902P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
ATE325117T1 true ATE325117T1 (de) 2006-06-15

Family

ID=29270728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03715209T ATE325117T1 (de) 2002-04-26 2003-04-15 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten

Country Status (15)

Country Link
US (1) US6713490B2 (https=)
EP (1) EP1499606B8 (https=)
JP (1) JP2005524696A (https=)
AR (1) AR039663A1 (https=)
AT (1) ATE325117T1 (https=)
AU (1) AU2003219398A1 (https=)
BR (1) BR0309778A (https=)
CA (1) CA2483636A1 (https=)
DE (1) DE60305026T2 (https=)
ES (1) ES2258716T3 (https=)
MX (1) MXPA04010549A (https=)
PA (1) PA8572601A1 (https=)
TW (1) TW200406402A (https=)
UY (1) UY27776A1 (https=)
WO (1) WO2003091241A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
WO2005035523A1 (en) * 2003-10-08 2005-04-21 Pfizer Japan Inc. Fused lactam compounds
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
EP1736474A4 (en) * 2004-04-07 2010-04-21 Kyowa Hakko Kirin Co Ltd piperidine
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2010036937A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
WO2010113109A1 (en) * 2009-03-31 2010-10-07 Link Research & Grants Corporation Treatment of tinnitus and associated auditory dysfunctions
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
KR20140146217A (ko) 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1991017156A1 (en) 1990-05-10 1991-11-14 Pfizer Inc Neuroprotective indolone and related derivatives
DK0666854T3 (da) 1992-10-30 1997-04-28 Pfizer Neurobeskyttende 3,4-dihydro-2(1H)-quinolon forbindelser
PE20020291A1 (es) 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda

Also Published As

Publication number Publication date
WO2003091241A1 (en) 2003-11-06
US6713490B2 (en) 2004-03-30
JP2005524696A (ja) 2005-08-18
PA8572601A1 (es) 2004-12-16
EP1499606A1 (en) 2005-01-26
TW200406402A (en) 2004-05-01
CA2483636A1 (en) 2003-11-06
DE60305026T2 (de) 2006-10-12
BR0309778A (pt) 2005-03-08
EP1499606B8 (en) 2006-08-30
DE60305026D1 (de) 2006-06-08
ES2258716T3 (es) 2006-09-01
UY27776A1 (es) 2003-11-28
AR039663A1 (es) 2005-03-02
AU2003219398A1 (en) 2003-11-10
US20030216430A1 (en) 2003-11-20
MXPA04010549A (es) 2005-02-17
EP1499606B1 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
ATE381565T1 (de) 1,3,8-triaza-spiro 4,5 decan-4-onderivative als neurokininrezeptorantagonisten
ATE284214T1 (de) Imidazo(1,2-a)-pyridinderivate als mglur5 antagonisten
ATE414074T1 (de) 2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl- piperidine als cgrp-antagonisten
ATE325117T1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
HRP20030031A2 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
IL173512A0 (en) Cyclopropyl derivatives as nk3 receptor antagonists
DE60133931D1 (de) Kondensierte purinderivate als a1-adenosinrezeptorantagonisten
DE60333866D1 (de) 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
DE60325613D1 (de) 5-Ä((2,3-difluorophenyl)methyl)thioÜ-7-äÄ(1S,2S)-2-hydroxy-1-(hydroxymethyl)propylÜaminoüthiazoloÄ4,5-dÜpyrimidin-2(3H)-on als CXCR2 Antagonist
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
ATE401333T1 (de) 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors
AP2005003196A0 (en) Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor.
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
DE60314238D1 (de) Kondensierte, bicyclische pyridinderivate als antagonisten des tachykininrezeptors
EP1809296A4 (en) NEW [1,4] -BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties